Zura Bio Ltd reports results for the quarter ended March 31 - Earnings Summary

Zura Bio

09/05/2025 15:56

Zura Bio Ltd ZURA.OQ reported a quarterly adjusted loss of 19 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -2 cents.  The mean expectation of eight analysts for the quarter was for a loss of 15 cents per share. Wall Street expected results to range from -18 cents to -10 cents per share.

Reported revenue was zero​; analysts expected zero.

Zura Bio Ltd's reported EPS for the quarter was a loss of 19 cents​.

The company reported a quarterly loss of $17.44 million.

Zura Bio Ltd shares had fallen by 2.3% this quarter and lost 49.6% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 10.3% in the last three months.​

In the last 30 days, four analysts negatively revised earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Zura Bio Ltd is $11.00

This summary was machine generated from LSEG data May 9 at 02:56 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.15
-0.19
Missed
Dec. 31 2024
-0.16
-0.10
Beat
Sep. 30 2024
-0.12
-0.26
Missed
Jun. 30 2024
-0.15
-0.17
Missed